When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Monique Burton, MD, Grace Katt, LAT, ATC; Julia Olson, MEd, LAT, ATC, CSCS; and Carlos Orlina, LAT, ATC, CES, PES, of @seattlechildren, discuss physical literacy and activity in…
